In the absence of a submission from the holder of the marketing authorisation, human normal immunoglobulin (Cuvitru®) cannot be endorsed for use within NHS Wales for use as a replacement therapy in adults, and children and adolescents (0-18 years) in: Primary immunodeficiency syndromes with impaired antibody production; Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra-indicated; Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients; Hypogammaglobulinaemia in patients pre- and post-allogeneic haematopoietic stem cell transplantation (HSCT).